Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
第一作者:
Milind,Javle
第一单位:
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mjavle@mdanderson.org.
作者:
医学主题词
老年人(Aged);胆道肿瘤(Biliary Tract Neoplasms);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);肿瘤转移(Neoplasm Metastasis);存活率(Survival Rate);美国(United States)
DOI
10.1016/S1470-2045(21)00336-3
PMID
34339623
发布时间
2021-09-21
- 浏览1
The Lancet. Oncology
1290-1300页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



